Below the Pfizer vaccine! The efficacy of mRNA-1273, the second new crown candidate vaccine in the United States, has been announced

On December 18, the U.S. Food and Drug Administration (FDA) approved emergency approval for the new crown pneumonia vaccine mRNA-1273 developed by U.S. biotech company Moderna, the second vaccine approved for use in the U.S. after the new BNT162b2 vaccine from Pfizer and BioNTech, a German biotech company.
a COVE study published December 30 in the New England Journal of Medicine, which evaluated data from mRNA-1273, a candidate vaccine for COVID-19 produced by Moderna.
this study proves that the vaccine, produced by Modern, can prevent new crown infections.
of the more than 30,000 subjects who were randomly vaccinated or treated with a placebo, 11 in the vaccine group developed new coronary symptoms, compared with 185 in placebo treatment.
data show that the effectiveness of the vaccine group is 94.1 per cent.
it is worth noting that serious new corona cases occur only in placebo treatment groups.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.NEJM, 2020.doi:10.1056/NEJMoa2035389.Moderna Vaccine has adverse events and side effects still need to be closely monitored in the United States A total of 30,420 adult subjects (79 percent white; 10 percent black or African-American; 20 percent Hispanic or Latino) were recruited at 99 sites, and none of the subjects had a new history of coronavirus infection.
July 27 to October 23, 2020, the subject received the first injection and 28 days later received the second injection.
the volume of each injection was 0.5 mL (containing 100 μg mRNA-1273 and physiological saline placebo).
second analysis of the efficacy of the mRNA-1273 vaccine, the efficacy of the vaccine focused on those who already had antibodies and those aged 65 and over.
study found that 30 subjects in the placebo group developed severe neo-coronary symptoms.
overall, adverse events were reported in the placebo and vaccine groups, with mild adverse reactions to the vaccine and moderate to severe side effects such as fatigue, muscle pain, joint pain and headache.
about half of the subjects experienced these side effects after the second injection, but most of the side effects disappeared between 15 hours and the next day after vaccination.
the short-term mRNA-1273 vaccine did not show an increase in respiratory diseases after infection.
in histological pathology, enhanced respiratory disease characteristics included Th2 tilt immune response, eosinophilic lung immersion.
the Th1 tilt vaccine response in advanced clinical evaluation of mRNA-1273 vaccine and preclinical trials of other new crown vaccines, and no pathological pulmonary immersion was seen.
incident follows reports that Bell's palsy was found in a BNT162b2 vaccine trial between Pfizer and BioNTech, a possibility that will also be closely watched in the mRNA-1273 vaccine trial.
According to the New York Times on December 25, a doctor in Boston said he developed a severe allergic reaction within minutes of receiving the Moderna vaccine, becoming the first allergy case in the United States after the Moderna vaccine was vaccinated nationwide.
he suffers from a severe shellfish allergy.
said in an interview that he had a severe reaction almost immediately after the vaccination, feeling dizzy and had an accelerated heartbeat.
Throughout the Moderna vaccine trial, the Safety Monitoring Committee continued to monitor new crown cases and serious cases, and subjects closely monitored adverse events in the weeks following the injection, and the researchers will collect all adverse events within two years of the injection. the difference between the
Moderna vaccine and the Pfizer vaccine mRNA-1273 vaccine is more effective at preventing new crown infections than the respiratory virus infection vaccine, and the mRNA-1273 vaccine for adult viruses has 59% efficacy data, based on short-term data.
the effectiveness of mRNA-1273 is close to that of the recently reported BNT162b2 mRNA vaccine (Pfizer vaccine).
December 10, 2020, NEJM confirmed that BNT162b2's 2-dose solution provides 95% protection against COVID-19 for people over 16 years of age.
vaccine was officially approved for emergency use by the FDA on December 11, 2020.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.N Engl J Med 2020; 383:2603-2615.doi:10.1056/NEJMoa2034577 Although both companies are mRNA vaccines, there are some differences: from In terms of efficacy, the Pfizer mRNA vaccine is 95% effective and the Moderna mRNA vaccine is 94.1%, and from the point of view of adverse reactions, both sides say there are no serious adverse reactions, but given that the mRNA vaccine is a new technology, the future must still be Further observation in phase IV. Clinically, from the point of view of storage temperature, Pfizer vaccine is extremely demanding on storage temperature and needs to be stored at a low temperature of -70 degrees C, and Moderna's mRNA vaccine can be stored for 6 months in an environment of minus 20 degrees C. The universality of the vaccine is greatly enhanced by the fact that the BioNTech vaccine is currently priced at $19.50 per dose in a regular refrigerator at 2-8 degrees C for one month and even at room temperature for 12 hours. It's cheaper than Moderna's $25-$37 per dose of vaccine; from a capacity perspective, BioNTech plans to supply 1.3 billion doses of vaccine worldwide by 2021, while Moderna expects to have 5-1 billion doses by 2021.
the global mRNA vaccine and treatment market reached 12.5 billion yuan in 2019 and is expected to reach 34.9 billion yuan in 2026, with a compound annual growth rate (CAGR) of 33.4%.
mRNA vaccine for infectious disease treatment is expected to account for 73.15% of the market by 2032.
, BioNTech, Moderna and CureVac are among the world's top three mRNA therapists, with BioNTech and Moderna at the forefront of research and development of the new crown vaccine.
: 1. Lindsey R. Baden et al, Efficacy and Safety of the mRNA-1273 SARSCoV-2 Vaccine, New England Journal of Medicine (2020). DOI: 10.1056/NEJMoa20353892. Mia Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not reproduced by any media, website or individual without authorization, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here